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Abstract
Increasingly, assays for the detection of anti-citrullinated peptide antibodies (ACPA) are used in
RA diagnosis. This review summarizes the biologic basis and development of ACPA assays,
available ACPA assays and their performance characteristics, and diagnostic properties of ACPA
alone and compared to rheumatoid factor (RF) in early RA. We also review correlations,
precision, costs and cost-effectiveness, availability, stability and reproducibility of the available
assays. Taken together, data indicate that ACPA has a higher specificity than RF for early RA,
good predictive validity, high sensitivity, apparent cost-effectiveness and good stability and
reproducibility. Given its superior performance characteristics and increasing availability, ACPA
is emerging as the most useful single assay for the diagnosis of RA.
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Introduction
The diagnosis of early rheumatoid arthritis (RA) has relied upon clinical criteria, including
history and physical exam findings, laboratory and radiographic results. Irreversible damage
frequently occurs early in RA (1-5). With mounting evidence supporting early diagnosis and
aggressive treatment to prevent damage and disability, there is need to improve
identification and diagnosis of early RA (6). Until recently, assays detecting rheumatoid
factor (RF), antibodies directed against the Fc portion of the immunoglobulin G (IgG)
molecule, have been the primary serological tests for RA diagnosis. Anti-citrullinated
peptide antibody (ACPA) assays, developed and commercialized in the past decade, are now
being employed clinically. Since ACPA are present before the onset of RA symptoms and
are predictive of RA development, they are a valuable diagnostic test early in the course of
the disease (4).
This review synthesizes currently available data regarding the diagnostic properties of RF
and ACPA for the diagnosis of early RA. We focus on ACPA given their recent
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development and their potential role in the improved identification of early, undifferentiated
RA. Data included in this review were obtained from medical literature searches, websites
and contact with companies marketing the assays, and information and opinions obtained
from experts in the field. We have included information on the biologic basis and
development of ACPA assays, the available assays, and data concerning assay performance
characteristics, in particular those published in peer-reviewed journals, but also those
publicized by manufacturers. Diagnostic properties of these tests, including, but not limited,
to sensitivity, specificity, positive and negative predictive values, are reviewed.
Rheumatoid factor (RF)
In 1940, Waaler observed that mixing serum from an RA patient with IgG-sensitized sheep
erythrocytes inhibited hemolysis, but caused cell agglutination (7). Rose and colleagues later
reported that RA sera agglutinated sheep erythrocytes coated with rabbit anti-sheep
erythrocyte antibody more than did sera healthy individuals (8). These findings formed the
basis of the earliest RA assay, the Waaler-Rose test.RF assays most commonly detect IgM
antibodies directed against the Fc portion of the IgG molecule. The agglutination test
measures RF IgM only and remains the most widely used assay. Agglutination assays are
reported as either titers or units. Cut-offs for positivity are determined by manufacturers and
based upon results from RA patients compared to healthy controls (4,9). Agglutination
assays have sensitivities for RA r from 70-85% and specificities ranging from 40-90%, as
agglutination in individuals without RA may occur (10-12).
Other assays for RF have been developed, including enzyme-linked immunosorbent assays
(ELISAs), radioimmune assays (RIAs), and laser or rate nephelometry techniques (13).
Assays for the detection of IgA and IgG RF are also available (14-19). The sensitivity of RF
for RA diagnosis by these techniques is 50-90% and specificity is 50-95%. These wide
ranges reflect differences in populations tested (20-26). Studies directly comparing RF
detection techniques in cohorts of established RA patients, healthy controls, and patients
with non-inflammatory joint disease, have reported latex agglutination test performance to
be similar to that of nephelometry and radioimmune assays (12,27). In a meta-analysis of 50
studies of RF assays from 1998-2005, the pooled likelihood ratios (dependent upon both
sensitivities and specificities) were quantitatively similar for IgM, IgA and IgG RF assays,
and for using a higher versus lower RF titer for positivity (26) (Table 1).
False positive RF results commonly occur in the setting of chronic infections, malignancy,
and other rheumatic diseases (21). RF is detected in the sera of 1-4% of healthy young
persons and in a higher percentage of elderly persons without RA (28,29). The RF assay
however, is widely available, relatively inexpensive, and understood by both primary care
physicians and arthritis specialists (21).
Antibodies to citrullinated peptides
In 1964, Nienhuis and colleagues described an autoantibody they called anti-perinuclear
factor. Detected by indirect immunofluorescence test on human buccal mucosa cells, anti-
perinuclear factor recognized antigen present in keratohyaline granules surrounding the
nucleus (30). Anti-perinuclear factor was present in up to 90% of established RA patients,
with a 73-99% specificity (31). Young and colleagues later detected anti-keratin antibodies
using indirect immunofluorescence on cryosections of rat esophagus (32). The reported
sensitivity of the anti-keratin assay in RA patients of 36-59% and specificity 88-99% (31).
Despite the high specificity for RA, these tests were not used widely because of difficulty in
standardization of natural substrates and arbitrary interpretation of the indirect
immunofluorescence pattern.
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In 1995, Sebbag and colleagues demonstrated that both of these antibodies belonged to a
family of autoantibodies directed against citrullinated fillagrin, an epithelial cell protein
(33). Citrullination is posttranslational modification of arginine to citrulline by the enzyme
peptidyl arginine deiminase (PAD). This process occurs naturally during inflammation,
apoptosis and keratinization (9). While fillagrin is not present in the synovium (34), several
citrullinated proteins, including fibrinogen and fibronectin, are present in RA synovium, and
other citrullinated epitopes have been identified as targets of highly RA-specific
autoantibodies (35-37). In 1998, Schellekens and colleagues produced synthetic linear
citrullinated peptides derived from human fillagrin, easily detected by ELISA with enhanced
sensitivity and no loss of specificity (35). To improve antigen composition and antibody
recognition, a cyclic citrullinated peptide (CCP) was developed (38).
The first commercially available ACPA assay (1st generation or CCP1) was developed by
Eurodiagnostica, used in early studies (2000–2001). This ELISA–based test employed a
single cyclic citrullinated peptide derived from fillagrin.(38). The assay detected
autoantibodies in 53% of established RA patients with 96% specificity (38).
Peptide libraries were then screened for better epitopes Since 2000, 2nd generation cyclic
citrullinated peptide (CCP2) and 3rd generation cyclic citrullinated peptide (CCP3) assays
have been developed. Several companies market these assays for RA diagnosis. CCP3
assays rely upon additional epitopes not present in the CCP2 antigen sequence (39,40).
Apart from the main difference in substrate, both CCP2 and CCP3 use ELISA methods and
similar dilutions (1:101), diluents, controls, conjugates, and rinterpretation. AxSYM Anti-
CCP utilizes microparticle enzyme immunoassay (MEIA) for the semi-quantitative
determination of the IgG class of auto-antibodies specific to CCP 2. Most studies, however,
show no evident improvement of CCP3 compared to CCP2 assays (41-43). The
compositions of many new CCP3 peptides are not yet publicly available as patents are
pending. The anti-CCP3.1 assay marketed by INOVA detects both IgG and IgA CCP3
antibodies in an effort to increase sensitivity (41). Eurodiagnostica has developed a “point-
of-care” assay, employing a finger lancet to obtain a drop of blood for rapid office-based
results.
Newer assays detect non-cyclic citrullinated peptides (41); the term anti-citrullinated peptide
antibody (ACPA) has thus replaced anti-cyclic citrullinated peptide (anti-CCP) antibody.
Citrullinated vimentin is present in synovial fluid. Anti-Sa antibodies, directed against it, are
detectable in RA synovium (44,45). Anti-Sa antibodies have reported sensitivity of 20-25%
and specificity of 95% in early RA (46). An ELISA for the detection of autoantibodies
against mutated citrullinated vimentin (anti-MCV) has better sensitivity than anti-Sa
antibody. The sensitivity of anti-MCV is comparable (or even higher in some studies) to that
of ACPA (82% vs 72%) (47), while specificity of anti-MCV is slightly lower than ACPA in
several studies (90-92% vs. 96-98%) (41,48). Unlike ACPA assays, the anti-MCV levels
may correlate with disease activity (47,49).
Pathogenetic role of ACPA in RA
The roles of citrullinated peptides and autoantibodies to them in RA pathogenesis remain
unclear. ACPA are strongly associated with an increased risk of developing RA in healthy
individuals and are detectable in the blood of healthy persons prior to clinical RA
(14,50,51). Among those with RA, their presence is associated with more severe structural
damage, radiographic progression and poorer response to therapy. (26,38,52-60,66).
Geneticists and epidemiologists hold ACPA-positive RA to be a homogeneous phenotype of
severe RA. ACPA is strongly associated with the HLA-DRB1 shared epitope (61) and
PTPN22 (62,63), strong genetic risk factors for RA, and smoking (64,65), the strongest
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known environmental risk factor for RA. Smoking by individuals with inherited HLA-DRB1
shared epitope genes may trigger RA-specific immune reactions to citrullinated peptides, the
generation of ACPAs and, ultimately, disease (64).
ACPA reproducibility and stability over time
In stored blood bank samples, Nielen and colleagues detected ACPA antibodies present up
to 14 years prior to RA onset, with gradually increasing prevalence and increased sensitivity
and specificity for RA compared to RF (51). The duration of the preclinical autoantibody
positive, symptom-free period prior to RA may iincrease with increasing age (60). In a 3-
year study off 97 individuals with RA, ACPA status was relatively stable: three ACPA
positive subjects became negative, while two ACPA negative subjects became positive (67).
Decreases in ACPA may be observed with some RA therapies, but generally patients do not
lose their positive results (68-72). Although in some small studies ACPA levels paralleled
RA disease activity (68,69,73-75), this has not been corroborated in subsequent studies and
ACPA assay results are not employed clinically to monitor disease activity (70-72).
Currently Available ACPA Assay Performance Characteristics
Several ACPA assays are currently approved by the U.S. Food and Drug Administration
(FDA) (Table 2). The ACPA assays employed by European and Canadian early arthritis
cohorts are mainly CCP2 assays (Diastat™ from Axis–Shield, Immunoscan-CCP Plus™
from Eurodiagnostica, and ELIA-CCP™ from Phadia, and Quanta Lite from Inova, etc).
Most currently available assays are kits employing a substrate derived from the synthetic
cyclic peptide described by Schellekens and colleagues (38,41), but differ in incubation
time, volume and dilution of serum, type of conjugate and of enzymatic substrate, and range
of units reported and thresholds for positive results (41,42,76-78). To determine the
diagnostic performance, manufacturers have tested established RA patients meeting the
1987 ACR criteria (79), and healthy individuals. Sensitivities range from 60-80% and
specificities from 85-99%. CCP2 assays have slightly higher sensitivity than CCP1 assays;
the newest non-cyclic ACPA assays report similar performance compared to CCP2
(42,76-78,80,81).
As ACPA assays are based on detection of autoantibodies by ELISA or MEIA or immuno-
enzymofluorimetry, reactivity is related to the quantity of antibody present in a non-linear
fashion. While changes in antibody concentration are reflected in a corresponding rise or fall
in results, the change is not proportional in most assays (i.e. a doubling of the antibody
concentration will not double the reactivity) (41). In a head-to-head comparison of the
technical performance of six different commercially available ACPA assays, Inova,
Eurodiagnostica and Genesis (41) demonstrated significant deviation from linearity; the best
linearity was achieved by Euroimmun.
ACPA assay precision
Studies comparing different ACPA assays have concluded that the majority of assays are
precise, with within-assay (intra-assay) coefficient of variations (CVs) for most available
assays ranging from 4-19% (41,78). In a study by Coenen and colleagues comparing six
ACPA assays, the greatest precision was found with Genesis (4.8-5.9% intra-assay CV) and
Inova assays (3.7-5.1% intra-assay CV) and the lowest with the Eurodiagnostica assay
(12.6-34.3% intra-assay CV) (41,78).
ACPA Assay correlation
Although different antigens and methods are employed to quantitate and report ACPA, the
results, expressed as positive or negative values, are highly correlated among commercially
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available ACPA assays, with correlation coefficients from 0.59 to 0.96 (Table 3) (41,78).
Vander Cruyssen and colleagues studied four ACPA assays, including INOVA’s CCP3
assay. They found that discrepancy between the ACPA assays was due to borderline results,
inter-assay variability and inter-test variability. The lowest intertest discrepancy is observed
between tests using the same substrate (82). If one false positive ACPA was found in an
individual without RA, there was a high probability that ACPA would be negative in a
different ACPA assay (82).
Development of an international reference range for standardized ACPA
reporting
Given the variety of ACPA assays, quantitative results are not currently comparable between
studies. Work is underway to develop standardized ACPA units. (83). Results were
promising, but require additional confirmation in large numbers of samples and acceptance
by assay manufacturers (84).
ACPA assays in other diseases
While the specificity of ACPA assays for RA compared to healthy individuals is good, the
potential for lower specificity in the setting of other inflammatory disorders, such as
psoriatic arthritis, scleroderma, systemic lupus erythematosus (SLE) and seronegative
spondyloarthropathies is of concern (85). The presence of immune complexes or other
immunoglobulin aggregates can cause increased non-specific binding and false positive
results.
We identified and reviewed 63 studies that examined the cross-reactivity rate of ACPA in
non-RA rheumatic diseases and common infections. The highest frequency of ACPA
positivity in non-RA autoimmune conditions are found in psoriatic arthritis (9%), SLE (8%),
and juvenile idiopathic arthritis (JIA) (8%), as well as scleroderma and CREST syndrome
(7%), followed by Sjögren’s syndrome (6%) and vasculitis (5%) (Table 4). As many patients
in these studies do not have long-term follow-up, they may have ultimately been diagnosed
with ACPA-positive RA or an overlap syndrome. For example, 7 of 126 psoriatic arthritis
patients with detectable ACPA had more severe, erosive disease and high prevalence of the
RA-associated HLA-DRB1 shared epitope (86). A high frequency of ACPA positivity has
been observed in patients with erosive arthritis and overlap syndromes with features of
scleroderma and SLE (41,43,78,82,87-91). ACPA in JIA has been associated with RF-
positive disease similar to RA in adults (92).
The surprisingly high prevalence of ACPA in active tuberculosis has been studied by
Kakamanu and colleagues (93). They reported that reactivity to uncitrullinated arginine-
containing residues was common in tuberculosis, but not in RA. The mechanism of
induction of ACPA in active pulmonary tuberculosis known. ACPA levels decreased
somewhat, but not rapidly, after treatment for tuberculosis (93).
Comparison of 1st, 2nd, and 3rd Generation and newer ACPA assays
Given the rapid evolution of ACPA assays, establishing the comparative sensitivity and
specificity of the three “generations” of assays is crucial if they are to be used
interchangeably. CCP2 and CCP3 assays offer slightly improved sensitivity over that of
CCP1 assays (85,94), although they have similar specificity for RA (86-96%). CCP2 and
CCP3 assays in most (41-43), but not all studies (91), have had similar performance
characteristics with sensitivities 68-79% and specificities 86-96% (26,43,75,78,81,95).
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New anti-MCV assays also have similar performance, with sensitivities 70-82% and
specificities 90-98% (47,48,96,97). Higher false positives rates have been reported with
Orgentec™ (anti-MCV) and Inova Quantalite™ (CCP3) assays (41). There is some lack of
agreement between the results obtained from different ACPA assays on same subjects,
which could be partially attributed to borderline results and inter-assay variability. One
study has shown 18% discrepancy between two different ACPA assays tested on RA
patients (82).
Cost and availability of RF and ACPA assays
RF assays have been widely used for years and are familiar to general practitioners. They
are relatively inexpensive and easy to obtain. Since 2000, when ACPA assays were first
introduced, the availability of these tests has drastically increased and costs have decreased.
They are now marketed almost worldwide by a variety of companies. The Diastat™ CCP2
assay from Axis-Shield, for example, is sold globally. It has the approval of the U.S. Food
and Drug Administration (FDA), the European Medicines Agency (EMEA) and the
Japanese Ministry of Health and Welfare (MOHW). The price per kit varies from market to
market, but is approximately $US 250-300 per 96 well kit. Immunoscan™ 2nd generation
ACPA assay 96 well kits from Euro-Diagnostica are currently marketed for 350-400€, $US
500-600, or £250-300 in Great Britain. Fully automated and point-of-care assays are
beginning to be marketed by several companies.
Konnopka and colleagues performed a cost effectiveness analysis to address the incremental
benefit of testing for ACPA in addition to the current ACR criteria for RA classification
(98). They developed a Markov model of the 10-year progression of RA in patients
presenting with undifferentiated arthritis, and estimated the effects of ACPA testing on
incremental costs and quality-adjusted life years, including the impact of late diagnosis and
treatment. Their analysis revealed that up-front use of ACPA testing, rather than waiting and
testing after a few years of symptoms, was cost effective, and, when indirect costs were
incorporated, saved in the range of 1000€ per quality-adjusted life year. While based on
multiple assumptions, this study does provide evidence for changing the current approach to
early inflammatory arthritis.
Diagnostic accuracy of ACPA assays
More than 300 studies have been published concerning the diagnostic accuracy of ACPA
assays in RA diagnosis (26). These studies vary substantially in focus: some have addressed
technical aspects, while others have compared the diagnostic accuracy in different
populations of individuals (early or established RA; patients with other diseases or healthy
controls). The studies are heterogeneous in their comparison of ACPA assay utility to other
tests, including IgM, IgA and IgG RF (26) and their use of a gold standard for RA diagnosis
(most often the existing 1987 American College of Rheumatology criteria for the
classification of RA (79)).
In studies of early or undifferentiated RA, ACPA testing is generally more specific and
equally sensitive to RF (Table 5). In cohorts containing both established and early RA, the
performance characteristics of the two tests are comparable (Table 4). The definition of
early arthritis or early RA has varied in these studies. In the majority, early arthritis has been
defined as symptom duration of less than 2 years (median of approximately 2 months) and
initial serologies of patients who developed RA have been compared to those who did not
(14,26,38-40,46,51,56,59,76,99-102,103,104,105,106,107-111). Most of these data are from
the prospective follow-up of early arthritis cohorts in Japan, the Netherlands, and Austria.
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RF and ACPA: One, either or both in Early, Inflammatory Arthritis?
Given the substantial overlap between the diagnostic performance and utility of RF and
ACPA for the diagnosis of RA, the marginal diagnostic value of adding one test to the other
and the added value of performing both must be addressed. In particular, the challenge is to
decide on the combination of assay or assays that offers superior performance for the
identification of RA among patients presenting with early, undifferentiated inflammatory
arthritis. Although correlated, RF and ACPA assays detect different underlying biological
phenomena in RA, and thus agreement between assay results is not static, but likely
fluctuates during disease course (103).
In our review of data from early RA cohorts, ACPA was slightly more specific than RF, but
the two assays have equivalent sensitivity (Table 5). The positive predictive value for ACPA
in the setting of early undifferentiated arthritis is 78-96% in t early RA cohorts, with most
values in the low to mid 90% range and the negative predictive value is 62-96%
(38,46,58,76,101,102,104,111). The positive predictive value for RF is broader, from
36-97% with most values in 70-80%, and the negative predictive value is 69-95%. Positive
ACPA results may be particularly helpful in the setting of a negative RF. The positive
predictive value of a positive ACPA test was 91.7% among 260 IgM-RF negative early
arthritis patients followed for one year (76). Employing both ACPA and RF positivity
further increases specificity and positive predictive value to above 95%, but decreases
sensitivity substantially. When either ACPA or RF positivity are required, the sensitivity is
somewhat increased (52-67%), but specificity is similar to that of RF alone (72-82%)
(102,104).
In cohorts containing both established and early RA, the performance characteristics of RF
and ACPA are comparable and the sensitivity of both RF and ACPA is improved,,(although
the ranges of performance characteristics are large and tdata are mixed). A strategy requiring
either ACPA or RF may improve sensitivity for both early and established RA. In one study,
the presence of either ACPA or RF increased testing sensitivity for RA from 66% (ACPA)
and 72% (RF) to 81%, with a good specificity of 91% (9). The specificity of requiring both
to be present is comparable to that of ACPA alone.
The addition of ACPA testing improved the sensitivity of the 1987 ACR criteria (which rely
upon the presence of RF as one of the 11 possible criteria, 4 of which must be present) for
the correct classification of early RA subjects (112). Adding ACPA results to the 1987
criteria increased sensitivity for early RA (≤ 6 month disease duration) from 25 to 44% and
did not change the specificity of 86%. ACPA also played an important role in a rule
developed by Van der Helm-van Mil and colleagues to predict which patients with
undifferentiated arthritis would progress to RA (113). Five hundred and seventy patients
with undifferentiated arthritis in the Leiden Early Arthritis Center were selected and
reassessed at one year for RA development. The prediction rule consisted of nine variables:
sex, age, location of symptoms, morning stiffness, tender joint count, swollen joint count, C-
reactive protein, and RF and ACPA positivity. ACPA was one of the strongest predictors,
and if positive, a subject received 2 points (113). A modified form of this prediction rule
was validated in three cohorts of patients with recent onset undifferentiated arthritis and was
found to have excellent discriminative ability to assess progression to RA (114).
ACPA assays are increasingly available and affordable. The assays have good predictive
validity as ACPA are associated with known genetic and epidemiologic risk factors for RA
and therefore identify a population of RA patients with more severe, erosive joint disease
that is at high risk for rapid joint destruction. Positive and negative results are highly
correlated between current assays. International standardization of reporting units is
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underway and will facilitate inter-assay comparisons. Both CCP2 and CCP3 assays have
improved upon CCP1 assays, and have comparable diagnostic utility, with sensitivities of
68-79% and specificities from 86-96% for RA (26,75,78,81,95)
We did not obtain all data, published and unpublished, from past comparisons of RF and
ACPA assay performance or perform a formal meta-analysis. We did review published
studies and presented sensitivity and specificity ranges of assays, alone and in combination
in both early and established RA cohorts. Our results suggest that ACPA assays offer a
slight advantage over RF (including high titer RF and combined IgM, IgA and IgG RF
levels) due to higher specificity. RF and ACPA are two different autoantibody systems that
do not measure or reflect the same underlying biology (103). While there is substantial
correlation between ACPA and RF seropositivity within patients, the ACPA assay may be
especially valuable in predicting RA in patients who are RF-negative but nevertheless have a
high probability of RA (76). If the role of the assay is to aid in the identification of patients
developing RA among those presenting with early undifferentiated symptoms, a high-risk
population with a high prevalence of disease (rather than screening the general population),
the positive predictive value of the ACPA assay is on the order of 95% (76).
ACPA assays have high specificity, high predictive validity, high specificity, apparent cost-
effectiveness and good reproducibility for the diagnosis of early RA. In prior studies,
accepting either ACPA or RF positive assay results for the diagnosis of RA did not improve
upon testing for RF alone and requiring both assays to be positive for diagnosis is a very
specific, but not extremely, sensitive approach. Ultimately, the decision to use one or both
tests depends upon the population tested, the indications for the testing, and the inherent
trade-off between sensitivity and specificity.
Summary and Overall Recommendations
• ACPA assays have good predictive validity in that they are associated with the
known genetic and epidemiologic risk factors for RA and identify a population of
RA patients with more severe, erosive joint disease, at high risk for more rapid
joint destruction.
• RF and ACPA are two different autoantibody systems and do not measure or reflect
the same underlying biology.
• ACPA assays are becoming increasingly available and less expensive. Cost-
effectiveness analyses suggest that up-front testing of ACPA in patients presenting
with undifferentiated arthritis is cost-effective, in particular in terms of the saved
indirect costs of delayed diagnosis.
• ACPA offers similar sensitivity, but higher specificity for RA than RF in early RA.
When used in the identification of patients potentially developing RA among those
presenting with early undifferentiated symptoms, a high risk population, (rather
than screening the entire population), the prevalence of disease will be high and the
positive predictive value of the ACPA assay is on the order of 95% (76).
• In the setting of a relatively high clinical suspicion (pre-test probability) and a
positive ACPA result, the patient has a high likelihood of having or developing RA.
If ACPA is negative, further testing may be indicated depending on the level of
clinical suspicion.
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Table 1






Pooled LR 4.86 (3.96-5.97) 0.38 (0.33-0.44) (9,14-17,19,25,27,39,40,44,
56,94,101,102,115-145)
RF Assay Type





5.05 (3.01-8.50) 0.39 (0.27-0.56) (9,27,44,102,115,117,120,
122,126,134,137-139,145,
146)




  ≥ 20 U/ml 4.42 (3.02-6.47) 0.39 (0.31-0.50) (26)
  ≥ 40 U/ml 5.49 (2.25-
13.38)
0.50 (0.37-0.69) (26)
  ≥ 80 U/ml 4.57 (4.60-8.17) 0.42 (0.34-0.51) (26)
LR: Likelihood ratio; RF: Rheumatoid factor.
Adapted from Nishimura K, et al (26).
Reprinted with permission from Annals of Internal Medicine.
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Table 4
Detection of ACPA in other diseases
n ACPA+ (n, %) Refs.
Psoriatic arthritis 1343 115 (8.6%) (41,78,82,86,87,152-156)
SLE 1078 84 (7.8%) (41,78,82,89-91)
Sjögren’s syndrome 609 35 (5.7%) (41,78,87,89,91)
Spondyloarthropathy 431 10 (2.3%) (78,89,104,149,155)
Scleroderma/CREST 380 26 (6.8%) (41,43,78,87,88,91)
Hepatitis C/cryoglobulinemia 285 10 (3.5%) (87,157,158)
Osteoarthritis 182 4 (2.2%) (78,87,89,91,149)
Hepatitis B 176 1 (0.6%) (159)
Juvenile idiopathic arthritis 169 13 (7.7%) (87,91,152,160-162)
Polymyalgia rheumatica 146 0 (0%) (89,91,149,163)
Vasculitis/ Wegener’s granulomatosis 107 5 (4.7%) (78,87,89,91,104)
Tuberculosis 96 33 (34.3%) (93,164)
Polymyositis/dermatomyositis 75 0 (0%) (41,78,82,87)
Fibromyalgia 74 2 (2.7%) (78,149)
Gout and pseudogout 58 0 (0%) (87,89,149)
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Table 5
Comparison of performance characteristics of RF and ACPA (CCP2) assays in early RA cohorts and cohorts
containing both early and established RA
ACPA (CCP2) IgM RF ACPA (CCP2) or IgM RF ACPA (CCP2) and IgM RF
Early RA Cohorts (38,46,58,76,101,102,104,106,111,119)
Sensitivity range, % 41-63 41-66 52-67 33-58
Specificity range, % 91-100 87-97 72-82 98-100
Early and Established RA Cohorts (9,41,82,96,102,106,120,124,133,155,165)
Sensitivity range, % 41-77 62-87 70-81 33-57
Specificity range, % 88-98 43-96 80-91 91-99
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